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The crystal structure of human cytosolic serine
hydroxymethyltransferase: a target for cancer chemotherapy
Suzanne B Renwick†, Keith Snell and Ulrich Baumann‡*
Background:  Serine hydroxymethyltransferase (SHMT) is a ubiquitous enzyme
found in all prokaryotes and eukaryotes. As an enzyme of the thymidylate synthase
metabolic cycle, SHMT catalyses the retro-aldol cleavage of serine to glycine, with
the resulting hydroxymethyl group being transferred to tetrahydrofolate to form
5,10-methylene-tetrahydrofolate. The latter is the major source of one-carbon units
in metabolism. Elevated SHMT activity has been shown to be coupled to the
increased demand for DNA synthesis in rapidly proliferating cells, particularly
tumour cells. Consequently, the central role of SHMT in nucleotide biosynthesis
makes it an attractive target for cancer chemotherapy. 
Results:  We have solved the crystal structure of human cytosolic SHMT by
multiple isomorphous replacement to 2.65 Å resolution. The monomer has a
fold typical for α class pyridoxal 5′-phosphate (PLP) dependent enzymes. The
tetramer association is best described as a ‘dimer of dimers’ where residues
from both subunits of one ‘tight’ dimer contribute to the active site.
Conclusions: The crystal structure shows the evolutionary relationship
between SHMT and other α class PLP-dependent enzymes, as the fold is highly
conserved. Many of the results of site-directed mutagenesis studies can easily
be rationalised or re-interpreted in light of the structure presented here. For
example, His151 is not the catalytic base, contrary to the findings of others. A
mechanism for the cleavage of serine to glycine and formaldehyde is proposed.
Introduction
Serine hydroxymethyltransferase (SHMT; EC 2.1.2.1) is a
ubiquitous enzyme that is central to one-carbon metabo-
lism in most organisms, including prokaryotes, eukaryotes
and archaebacteria. To date, the amino acid sequences of
SHMTs from 32 species have been deposited in the
SWISSPROT data bank and exhibit sequence identities
varying between 32% and 93%. SHMT is a pyridoxal
5′-phosphate (PLP) dependent enzyme and has been
assigned to the α class of PLP enzymes [1], but it exhibits
only very low sequence identity with other members of
this family (e.g. aspartate aminotransferase). The major
physiological reaction catalysed by SHMT is depicted in
Figure 1 and involves the retro-aldol cleavage of serine to
glycine, with the one-carbon unit being transferred to
tetrahydropteroylglutamate. The resulting 5,10-methylene-
tetrahydropteroylglutamate (5,10-methylene-tetrahydrofo-
late) is the major one-carbon donor for the biosynthesis of
thymidylate, purines, methionine and choline. In addition
to the physiological reaction, SHMT has also been shown to
catalyse transaminations, racemisations, and decarboxyla-
tions, at least in vitro (for a review see [2]).
Of the trio of enzymes involved in the thymidylate syn-
thase cycle, SHMT is the only enzyme yet to be studied
clinically as a target for cancer chemotherapy. The
5,10-methylene-tetrahydrofolate produced by SHMT par-
ticipates directly in pyrimidine biosynthesis by donating a
methyl group used for methylating 2′-deoxyuridine
monophosphate (dUMP) to 2′-deoxythymidine monophos-
phate (dTMP), and indirectly in purine biosynthesis via its
conversion to 10-formyltetrahydrofolate. The glycine pro-
duced in the SHMT reaction can also be utilised in purine
biosynthesis, providing two carbons and a nitrogen of the
purine ring.
With both reaction products involved in nucleotide
biosynthesis, it is not surprising that elevated SHMT
activity has been found in human leukaemic cells [3] and
in a variety of solid tumour tissues of human and rodent
origin [4]. Furthermore, a positive correlation of SHMT
activity with tumour growth rate was found in Friend
mouse leukemia and Pliss rat lymphosarcoma models [5].
However, for serine to be preferentially channelled
towards nucleotide biosynthesis requires a reorientation
of the enzymes involved in its synthesis and utilisation.
Evidence for such a reorganisation can be seen in tumours
of hepatic origin where the increased activities of
enzymes involved in serine biosynthesis are accompanied
by the retention of SHMT and the simultaneous deletion
of the two enzymes involved in serine catabolism —
serine aminotransferase and serine dehydratase [4,6,7].
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Consequently, the increased capacity for serine biosyn-
thesis is coupled specifically to its utilisation for
nucleotide biosynthesis as a part of the biochemical com-
mitment to cellular replication in cancer cells. This obser-
vation signifies the importance of SHMT as a therapeutic
target for cancer treatment. Indeed, inhibition of the
enzyme in myeloma cells in culture results in dose-depen-
dent inhibition of cellular growth [8].
The crystal structures of the other two enzymes of the
thymidylate synthase cycle, dihydrofolate reductase [9,10]
and thymidylate synthase [11,12], have already been
determined. Both enzymes have proven to be clinically
successful targets for anticancer chemotherapy [13,14].
Analogues of dihydrofolate, such as methotrexate, are
potent inhibitors of dihydrofolate reductase and have
been used clinically as anticancer agents for over 50 years.
Agents such as fluorouracil, and the newer antifolate drug
Tomudex, have proved to be effective inhibitors of
thymidylate synthase and are clinically established drugs
in the treatment of cancer. Drugs targeting these enzymes
have also been used as antibacterial and antiprotozoal
agents by exploiting the differences between the catalytic
sites of isoenzymes from the host and target organism
[15–17]. With such considerable effort put into designing
drugs against these enzymes, it is surprising that so little
attention has been paid to the inhibition of SHMT.
Whereas inhibition of the other enzymes preferentially
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Figure 1
Proposed reaction cycle catalysed by SHMT.
Initially, the cofactor PLP is covalently bound
as a Schiff base to the sidechain of Lys257.
The retro-aldol cleavage is the reaction step
leading from intermediate II to III and involves
deprotonation of the serine external aldimine
by an unidentified base (B). The second
product of this step, formaldehyde, reacts with
tetrahydrofolate to form 5,10-methylene-
tetrahydrofolate. The absorption maxima of
some intermediates are indicated in nm.
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Structure
disrupts pyrimidine biosynthesis, drug targeting of SHMT
would have the advantage of blocking DNA synthesis by
the concurrent action on both pyrimidine and purine
biosynthesis. This highlights the feasibility of using the
three-dimensional structure of this enzyme in the design
of a clinically useful SHMT inhibitor.
In eukaryotes there are cytosolic and mitochondrial iso-
forms of SHMT. Human cytosolic SHMT (cSHMT)
exists as a homotetramer, with each monomer binding a
single PLP cofactor. In the absence of an X-ray crystal
structure, past studies have been performed by chemical
modification and site-directed mutagenesis based on
amino acid residues that are totally conserved across the
known SHMT protein sequences. Much of this work has
concentrated on the dimeric enzyme from Escherichia coli
[18–22] and on the tetrameric sheep liver enzyme [23,24]. 
A rational interpretation of these results requires a
knowledge of the three-dimensional structure of the
enzyme. The successful crystallisation of the E. coli
enzyme has been published [25], but as yet no structure
has been reported. We report here, for the first time, the
crystal structure of human recombinant cSHMT. The
structure reveals a fold typical for α class PLP-depen-
dent enzymes and a tetrameric architecture best
described as a ‘dimer of dimers’. The active-site residues
can be readily correlated with the results of biochemical
and mutagenesis studies.
Results and discussion
Refinement
Some relevant refinement statistics are shown in Table 1.
The final model contains residues 11–480, one PLP mol-
ecule and 97 water molecules. Residues 1–10 and the
attached His-tag are completely disordered, whereas
residues 275–280 have weak density. Cys110, which is
located at the surface, is apparently covalently modified
but the ligand could neither be modelled as dithiothreitol
nor glutathione and its chemical nature remains unclear at
the present time. All other cysteine residues are in the
reduced form. As expected with cytosolic proteins, there
are no pairwise arrangements of cysteines indicative of the
possible presence of a disulphide bond.
The compatibility of the primary sequence and three-
dimensional fold was confirmed using the program ProsaII
[26]. The z scores for Cβ–Cβ pair potentials, surface and
combined energies are –8.80, –7.47 and –11.62, respec-
tively, and are well within the range expected for native
protein folds. All other conformations tested exhibited
much worse z scores.
The overall B factor is quite high which probably originates
from the high solvent content, no sigma cut-off and the
inclusion of bulk-solvent corrected low-resolution terms. 
Backbone conformation
The Ramachandran plot shows that 97% of all residues
fall into the core region as defined by Kleywegt and
Jones [27]. The two most prominent outliers are Glu133
and Lys257. Both residues can be shifted to energetically
more favourable regions by flipping the preceding
peptide bonds. In the case of Glu133 this flip would
create too close a contact between the carbonyl oxygens
of residues 128 and 132, whereas in the ‘Ramachandran-
forbidden’ conformation this interaction is converted to a
hydrogen bond between the carbonyl oxygen of residue
128 and the amide nitrogen of residue 132. Similarly,
Lys257 forms a hydrogen bond between the carbonyl
oxygen of residue 256 and the amide nitrogen of residue
259. Difference electron densities of the ‘flipped’ (i.e.
‘Ramachandran-allowed’) conformations seem to indi-
cate that the original strained model is correct. In the
case of Lys257, a comparison with tyrosine phenol-lyase
(TPL) indicates a similar, although not identical,
strained conformation for this residue. Of course, the
usual caveats hold for all these residues with respect to
the limited resolution of the crystal structure. Pro298 is
in the cis-conformation; the electron density is unam-
biguous here, so we believe that this is correct despite
the limited resolution.
Crystal packing
There is only one kind of crystal contact found in the struc-
ture, which involves the ‘small’ domain (see below). The
contacts are symmetrical and involve stretches around
residues 346, 423 and 467. The intertetramer contacts are
created by the 62 screw operation and hence are along the
c axis. As can be seen from Figure 2, the molecules pack
most densely along the c axis and there are only intrate-
tramer contacts in the a,b plane, which is consequently
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Table 1
Refinement statistics.
Resolution range (Å) 40.0–2.65
Number of reflections 48,595
Number of atoms (total) 3710
Number of solvent molecules 97
Observable/parameter ratio 3.0
R/Rfree* 0.210/0.226
Average B factors
all atoms (Å2) 61.1
solvent (Å2) 53.2
PLP (Å2) 53.5
Root mean square deviation
bonds (Å) 0.006
bond angles (°) 1.2
dihedrals (°) 22.4
impropers (°) 1.1
B (bonded atoms) (Å2) 3.4
Residues in core Ramachandran (%) 97
*R = ∑ |Fo–Fc| / ∑ Fo. The Rfree was calculated using a test set of 2760
reflections.
much more loosely packed. This observation explains the
anisotropic diffraction properties of the crystals.
Monomer structure
The overall fold (Figure 3) of the monomer of human
cSHMT is similar to that of other PLP-dependent
enzymes of the α class, such as aspartate aminotransferase
(AAT) [28]. A search for structural homologues using the
program DALI [29] identified TPL [30] (apo form, PDB
code 1TPL; z score 20.9), dialkylglycine decarboxylase
(DKB) [31,32] (PDB code 2DKB, z score 20.8), AAT
[28,33] (PDB code 7AAT, z score 18.1) and ornithine
decarboxylase (ORD) [34] (PDB code 1ORD, z score
16.5) as the most similar structures in the database. The
structures of two other similar PLP-dependent enzymes
have been solved, namely ω-amino acid aminotransferase
[35] and cystathionine β-lyase [36], the latter belonging to
the γ class. The coordinates of these two structures are
currently unavailable. Clearly, all of these enzymes have
the same characteristic fold (Figure 3c), which will be
described briefly in the following section.
The monomer fold can be described in terms of three
domains (Figure 3): the N terminus, the ‘large’ domain
and the ‘small’ domain. The first domain, the N termi-
nus (residues 11–53), mediates intersubunit contacts and
folds into two α helices and one β strand. The second
(large) N-terminal domain (residues 53–321) binds PLP.
This domain is very similar to the corresponding cofac-
tor-binding domains in AAT, ORD and TPL. It basically
folds into an αβα sandwich containing nine α helices
wrapped around a seven-stranded mixed β sheet. The
sheet topology is –5x,–1x,2x,1x,1x,1, in Richardson’s
notation [37], with right-handed cross-over connections.
The sheet is shielded from the solvent by five helices on
one side and by three helices on the other. Finally, the
C-terminal small domain (residues 322–480) folds into an
αβ sandwich. The antiparallel β sheet has –1,–2x,1 
topology. This sheet packs on one side against the large
domain and is shielded from the solvent by four helices
on the other side. The interdomain contacts are medi-
ated by segments 143–146, 175–180, 204–207 and
354–359. The long helix h13 (residues 322–345) has been
assigned to this small subunit, largely to maintain consis-
tency with earlier assignments in AAT and TPL. This
helix connects the large and the small domain and, in
contrast to the corresponding helix in AAT, exhibits only
a slight bend.
Quaternary structure
Human cSHMT is a tetramer in solution and this
oligomeric architecture is also observed in the crystals
(Figure 4). The tetramer is a crystallographic one, that is,
the centre of the molecule occupies a special position in
the crystal lattice with 222 (D2) symmetry.
The four protomers interact with each other to signifi-
cantly different degrees; upon tetramer formation a
surface of 22,232 Å2 becomes buried. Formation of the
‘tight’ dimers A–D and B–C buries 9249 Å2 each, whereas
formation of the dimers A–C and B–D buries 39 Å2 each
and A–B and C–D each bury 1849 Å2 . These data show
that the tetramer is best described as a dimer of dimers.
This situation is very similar to the one seen in DKB, but
quite different from the oligomer association in TPL,
where a more symmetrical interaction is found.
All mammalian SHMT proteins examined so far have been
found to be tetramers. In contrast, the E. coli enzyme has
been described as both a tetramer and dimer, dependent
on the expression level in E. coli. Under native conditions,
however, the enzyme appears to be a dimer [38]. From the
discussion above it is easy to rationalise why SHMT can
have a dimeric or tetrameric quatenary structure: the func-
tional entity is a dimer and tetramer formation does not
require the rebuilding of a large number of contacts.
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Figure 2
Stereoview showing crystal packing. The
small domain is coloured in red, the large
domain is in green, and the N terminus is in
magenta. The tetramer is a crystallographic
one; each small domain mediates crystal
contacts to one other small domain of a
different tetramer.
Structure
Site-directed mutagenesis studies on sheep liver SHMT
[25] revealed that His134, corresponding to His135 in the
human cytosolic enzyme, is involved in tetramer forma-
tion. His135 in the human enzyme is positioned in the
very centre of the tetramer (Figure 5). The imidazole
sidechain ring of a particular subunit stacks onto the
equivalent ring of another subunit, that is, the interactions
are His135(A)–His135(B) and His135(C)–His135(D). Fur-
thermore, within the same subunit the sidechain of
His135(A) is hydrogen bonded to Glu168(A) which, in
turn, forms a hydrogen bond to Arg137(B) of a neighbour-
ing subunit. Hence, it is easy to understand why substitut-
ing histidine for asparagine can interrupt the tetramer
whilst leaving the tight dimers intact. The dimeric E. coli
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Figure 3
The overall fold of the SHMT monomer. 
(a) Stereoview ribbon diagram of the
monomer. The N terminus is shown in purple,
the small domain in red and the large domain
in green. The cofactor PLP is shown in ball-
and-stick representation. (The figure was
prepared using MOLSCRIPT [61] and
Raster3D [62].) (b) Stereoview Cα plot of the
monomer with residue numbering. The
domains are coloured as in (a). (c) Stereoview
Cα overlay of SHMT (black), dialkylglycine
decarboxylase (DKB; red) and aspartate
aminotransferase (AAT; green).
enzyme possesses a glycine residue at position 135, which
is entirely consistent with the interpretation above. It is,
however, difficult to explain why the mutant enzyme
binds PLP much more weakly than the wild-type enzyme,
because interactions with PLP occur only within the tight
dimer. Alternatively, one could assume that the dimer
observed in the mutant SHMT is not the catalytically
active tight A–D dimer but rather the ‘loose’ A–B dimer.
Nevertheless, it would be difficult to imagine how a single
mutation could disrupt the tight dimer interface so com-
pletely and yet the loose dimer (e.g. A–B) could still retain
some catalytic activity.
The N terminus is very important for the formation of the
tight dimer. Site-directed mutagenesis studies on the
sheep liver enzyme [39] have revealed that N-terminal
truncation destabilises the protein. The basis for this can
be seen from Figure 4: the two N-terminal helices act as
clamps that are crucial for stabilisation of the tight dimer.
The active site
The cofactor PLP is covalently bound to Lys257 in the
active site of the molecule (Figures 6 and 7). The proto-
nated N1 nitrogen of the pyridine ring is hydrogen
bonded to Oδ1 of Asp228 which, in turn, is hydrogen
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Figure 4
Stereoview cartoon representation of the
SHMT tetramer. Subunit A is coloured in
cyan, B in brown, C in green and D in purple.
A–D and B–C form the ‘tight’ dimers, which
are related by a horizontal twofold axis. Bound
PLP cofactor is shown in space-filling
representation.
Figure 5
Stereoview of the tetramer centre showing the
central role of His135. The carbon atoms of
the A, B, C and D subunits are coloured in
purple, green, cyan and black, respectively.
For the sake of clarity, only two of the four
hydrogen-bond networks involving His135
and its symmetry-related mates are drawn
(dashed lines).
bonded to the Nε1 of His151. The other carboxylate
oxygen of Asp228 accepts a hydrogen bond from the main-
chain amide nitrogen of Ala230. One side of the pyridine
ring of the cofactor is stacked onto the imidazole ring of
His148. This interaction is also present in ORD where the
cofactor stacks onto His223, while in AAT and DKB this
histidine residue is replaced by a tryptophan. On the other
side, the pyridine ring is held in place by Ala230, a residue
that is conserved in AAT and ORD, but not in TPL where
it is replaced by a threonine. The phosphate group of PLP
is hydrogen bonded to various residues, including Tyr73′
and Gly303′ from a neighbouring subunit. The O3′ of
PLP is hydrogen bonded to the sidechains of Ser203 and
His231, both residues being strictly conserved in all
SHMT protein sequences. Not surprisingly, the two sub-
units forming the active site are the same two that form
the tight dimer (A–D).
The similarity between the active sites of AAT, ORD and
SHMT is revealed by their overlay shown in Figure 7. In
particular, ORD and SHMT share the feature that the
PLP-binding lysine residue is preceded by a histidine,
making these two proteins members of a distinct subclass
within the α class of PLP-dependent enzymes.
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Figure 6
The active site of SHMT. (a) Stereoview
active site cartoon depicting key residues. The
A and D subunits are shown as orange-brown
and cyan traces, respectively. PLP carbon
atoms are shown in green, carbon atoms in
black, oxygens in red, nitrogens in blue and
phosphorus in yellow. Hydrogen bonds are
shown as dotted lines. (b) Stereoview Fo–Fc
‘omit’ electron-density map overlaid on the
final model. The contour level is 3σ. (c)
Stereoview showing a tentative model of the
serine–PLP complex. The same colour
scheme is used as for (a).
In previous investigations the role of some amino acids
conserved between SHMT sequences has been probed by
site-directed mutagenesis. These results can be readily
interpreted with the structural data now available.
His256 has been implicated in reaction specificity [19].
Besides the physiological reaction outlined in Figure 1,
SHMT can catalyse L- and D-alanine transamination
and racemisations, but exhibits strict reaction speci-
ficity with its natural substrates glycine and L-serine.
The reaction pathway is stereoelectronically controlled
by the requirement that the group to be released must
be oriented orthogonal to the pi-bond system of the
pyridoxal ring. Therefore, it has been suggested that
His256 binds to the γ-hydroxyl group of the serine and
orients it with respect to the PLP-ring plane. Prelimi-
nary modelling of the serine-aldimine was carried out
using the analogous structures of AAT and aligning the
serine carboxylate group with the Arg402 guanidino
group. In this simple model, which does not take into
account any possible conformational changes in the
protein, the distance between His256 and the serine
sidechain is too large for any direct interaction to take
place (Figure 6c).
Catalytic base
One of the possible reaction mechanisms for the conversion
of serine and tetrahydrofolate to glycine and methylene-
tetrahydrofolate involves a retro-aldol cleavage [40,41]
(Figure 1). This mechanism requires that a catalytic base
abstracts the proton from the γ-hydroxyl group of serine; the
resulting formaldehyde is transferred in a condensation
reaction onto tetrahydrofolate, yielding methylene-tetrahy-
drofolate. The catalytic base has not been identified so far
in SHMT. Whereas in AAT the PLP-attachment lysine
residue has been implicated as the catalytic base [33,42],
site-directed mutagenesis studies indicated that this is not
the case in SHMT [20] and ORD [34]. Mutagenesis studies
performed on sheep liver SHMT were carried out to replace
the conserved residues His134, His147 and His150 (corre-
sponding to His135, His148 and His151 in human cSHMT)
with asparagine [24]. These studies revealed that His135 is
involved in tetramer contacts (see above), His148 in PLP
binding and formation of the dimer interface, and His151
has been implicated as the catalytic base. On the basis of our
structure we can now readily account for these findings.
Mutation of His148 leads to the loss of PLP and partial
dimer disruption. As mentioned above, His148 stacks onto
1112 Structure 1998, Vol 6 No 9
Figure 7
Steroview comparisons of the active sites from
different PLP-dependent enzymes.
(a) Overlay of the active sites of aspartate
aminotransferase (AAT; cyan) and SHMT
(green). (b) Overlay of ornithine decarboxylase
(ORD; cyan) and SHMT (green).
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(a)
(b)
the pyridine ring of the PLP and thus is crucial in cofactor
binding. Because the phosphate moiety of PLP makes
contact to the other subunit of the tight dimer, loss of PLP
leads to a weakened dimer–dimer interaction.
His151 stabilises, via hydrogen bonding, the negative
charge on Asp228 which is crucial for stabilising the posi-
tive charge at the N1 of the PLP cofactor. Protonation of
the PLP pyridine ring is important for the electron-with-
drawal properties of PLP. Hence, the loss of activity by
mutation of His151 is readily explained, but His151 is
clearly not the catalytic base.
As mentioned previously, in the case of AAT and cys-
tathionine β-lyase [36] the lysine residue attaching to the
cofactor has been implicated as the catalytic base, whereas
in SHMT it was deduced that another residue must fulfil
this role. This is slightly surprising in terms of evolution-
ary relationships between these enzymes and prompted us
to find other possible candidates.
Besides Lys257 there are two other residues which could
act as the catalytic base, Glu75(D) and Tyr83(D)
(Figure 6c), both from the partner subunit (D) of the tight
dimer. Both residues are absolutely conserved amongst
the various SHMT sequences. The sidechain of Tyr83(D)
is not well defined in the electron-density map. Glu75(D)
is well defined and in a suitable position to abstract the
proton from the γ-hydroxyl group of the external aldimine,
as a crude modelling of the serine–PLP complex indicates
(Figure 6c). Other residues that are within hydrogen-
bonding distance include Ser53 and His231. His231 coor-
dinates to the O3′ of the cofactor in a way similar to
Tyr225 in AAT.
Serine- and tetrahydrofolate-binding sites
In the absence of bound substrates it is assumed that α
class PLP-dependent enzymes exist in the ‘open’ or ‘half-
open’ conformations (i.e. the conformation observed in
our crystals). Arg402 has been implicated as the residue
that binds to the carboxylate group of serine/glycine [21]
and is well positioned to fulfil this role. We are not able to
assign the tetrahydrofolate-binding site from the current
data. Nevertheless, a possible hint might come from the
conserved Arg263 residue, which is present in the active
site and might bind to the carboxylate groups of tetrahy-
drofolate. Arg263 is conserved in all SHMT sequences,
with the exception of those of the archaebacteria. The
sidechain of this residue is completely buried by the
D subunit and there is no group that could neutralise its
positive charge. Such binding to tetrahydrofolate would
require substantial conformational changes.
The catalytic mechanism
On the basis of mutagenesis data and our crystal structure,
we suggest that the retro-aldol cleavage mechanism is the
most likely explanation of catalysis. Alternatively, a so-
called thiohemiacteal mechanism has been discussed [41].
This mechanism involves the nucleophilic attack of a cys-
teine S-γ on the β carbon of the serine yielding a thio-
hemiacteal. The same cysteine reacts with fluoroalanine
intermediates to form an inactive adduct. Cys204 has been
identified as the residue reacting with fluoroalanine or
similar suicide inhibitors of SHMT. As outlined above, we
do not believe that this thiohemiacteal mechanism is oper-
ating in the physiological reaction but nonetheless the
inactivity of the modified protein has to be explained.
From our observation that all cysteine-modifying agents
cause fracture damage to the crystals, it appears reasonable
to assume that a conformational change involving the small
subunit occurs. It is plausible that modification of Cys204
leads to a conformational change involving the small
subunit, similar to the one observed in AAT [33,42]. This
conformation is inappropriate for the effective propagation
of the reaction (e.g. it might be in the closed conformation).
Modification of Cys204, which sits at the interface between
the large and small domains, would lock the enzyme, pre-
venting any further participation in the reaction.
Biological implications
Serine hydroxymethyltransferase (SHMT) is a central
enzyme in one-carbon metabolism, catalysing the trans-
fer of the β-hydroxyl group of serine to tetrahydrofolate
to create 5,10-methylene-tetrahydrofolate. The latter is
the major source of one-carbon units in cellular metabo-
lism and is both directly involved in pyrimidine biosyn-
thesis and indirectly involved in purine biosynthesis.
Elevated levels of SHMT activity have been found in
rapidly proliferating cells, particularly in tumours and
various cancer cell lines. Of the three enzymes partici-
pating in the thymidylate synthase metabolic cycle,
SHMT is the only one yet to be exploited as an anti-
cancer target. The rational development of a tight-
binding inhibitor of the enzyme has been hampered by
uncertainties over its catalytic mechanism and the com-
plete lack of any three-dimensional protein structure
from any species. Furthermore, although data from
chemical modification and site-directed mutagenesis
studies have been reported, the interpretation of the
findings has been constrained by the absence of any
structural model of the enzyme. 
The crystal structure of human cytosolic SHMT, pre-
sented here for the first time, reveals that the enzyme
belongs to the α class of pyridoxal 5′-phosphate (PLP)
dependent enzymes. The tertiary fold of these proteins
shows the monomer to comprise essentially two
domains where the larger N-terminal domain binds the
PLP cofactor. In the case of SHMT, the active site is
constructed by residues from two different subunits of
the tetrameric enzyme.
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On the basis of the present structure, amino acids impli-
cated in substrate binding and catalysis can be identified
for further site-directed mutagenesis studies. Such
research will aid the understanding of the catalytic
mechanism of action of this enzyme. Furthermore, the
protein structure will also be of considerable value in the
rational design of enzyme inhibitors which may prove to
be useful in anticancer chemotherapy.
Materials and methods
Over-expression, purification and crystallisation
Details of the purification and crystallisation have been published else-
where [43]. Briefly, a cDNA encoding human cSHMT was isolated
from the ZR75-1 breast cancer cell line cDNA library (P Byrne, per-
sonal communication). SHMT cDNA was amplified by PCR and ligated
into Nde I digested pET-14b (Novagen). Over-expression was carried
out in E. coli strain BL21(DE3)pLysS (Novagen). SHMT was then puri-
fied in one step by metal chelation chromatography, a typical yield was
~15 mg of soluble, pure cSHMT from 1 litre of bacterial culture.
Crystals were obtained using the commercial Crystal Screen kit
(Hampton Research, Laguna Hills, CA, USA) [44] with Hampton
Crystal Screen reagent 25 (1.0 M sodium acetate, 0.1 M imidazole
pH 6.5). Hexagonal bipyramidal crystals were observed after 1–2 days
and grew to a typical size of 0.3 × 0.3 × 0.8 mm3 within one week. The
crystals belong to space group P6222 with cell-dimensions
a = b = 155.0 Å, c = 235.5 Å and contain ~82% solvent which results
in the surprisingly high Matthews parameter of 7.5 Å3/Da. Later, a
slightly different crystal form was produced with cell dimensions
a = b = 154.1 Å, c = 235.4 Å. These small changes in the unit cell
between the two crystal forms gave rise to significant intensity differ-
ences in the order of 12–16%.
Data collection and structure solution
The average life span of the cSHMT crystals on a rotating-anode
source was less than 10 min. Consequently, crystals were flash-cooled
to 110K prior to data collection. Glycerol was introduced by serial
transfer of crystals into crystallisation buffer containing 5–30% (v/v) of
the cryoprotectant. Data were collected in-house using a Rigaku
RU200 rotating-anode generator operating at 5.4 kW with double
focusing mirrors, and a Raxis IIc detector. Data were collected on each
crystal in frames of 0.8° rotation and with an exposure time of 20 min
per frame. The crystal-to-detector distance was 250 mm with a swing
angle of 9°. In addition, data were collected at beam line BW7B at the
EMBL outstation in Hamburg at the DORIS storage ring, DESY, using
a 30 cm MAR image plate at a wavelength of 0.9995 Å. All data were
processed using the HKL suite [45].
Some data collection statistics are given in Table 2. As the complete-
ness in the shell between 2.63 and 2.60 Å was fairly low, we restricted
the resolution range to 2.65 Å. The completeness of the merged data
set native 2 plus native 3 is 0.97 in the shell between 2.68 and 2.65 Å
and the average I/σ(I) is 2.7 in this shell.
Preliminary trials to solve the structure by molecular replacement were
unsuccessful which was not too surprising considering the low
sequence homology between SHMT and other PLP-dependent
enzymes. Hence, structure solution was effected by the method of iso-
morphous replacement.
Heavy-atom derivatives were prepared by soaking crystals in mother
liquor containing an appropriate amount of the heavy-atom reagent.
Most mercury and platinum compounds destroyed the crystals very
quickly; one nonisomorphous mercury derivative was prepared by
applying a mixture of mercury(II) acetate and cysteamine [46]. Other
heavy-atom compounds caused severe changes in the a axis cell
dimension and these derivatives were useless beyond 6 Å resolution.
Selenomethionine-substituted protein was prepared from E. coli
B834(DE3)pLysS cells (Novagen) [47]. Eventually, a set of five deriva-
tives were found. Derivative data were locally scaled to native data
using MAXSCALE [48]. The potassium osmate (KOS) derivative could
be interpreted in terms of one major heavy-atom site using SHELX
[49]. Further heavy-atom positions were determined by difference Pat-
tersons and difference Fourier methods. Most crystallographic compu-
tations were effected using CCP4 [50]. Phases were computed using
MLPHARE [51] and later SHARP [52]. The program SHARP, which
incorporates a full maximum-likelihood procedure, gave superior
phases and aided the discovery of minor sites. Phasing statistics are
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Table 2
Data collection and phasing statistics.
Data set No. of reflections Resolution Rsym* Completeness <I>/<σ> Riso† No. of Phasing power‡ Rcullis
measured/ (Å) overall/ overall/ sites acentric/ (centric)§
unique last shell last shell centric
Native 1 158,836/28,884 3.0 0.058/0.247 0.857/0.446 21.1/2.71 – – – –
KOS10 154,022/29,555 3.1 0.083/0.804 0.971/0.905 19.4/2.3 0.21 4 3.0/2.4 0.55
KOS20 194,655/20,757 3.3 0.092/0.532 0.970/0.880 22.7/3.3 0.25 4 3.1/2.4 0.59
PIP 78,169/19,647 3.5 0.105/0.403 10.5/1.4 0.29 3 3.3/2.9 0.53
PIP05 107,150/26,066 3.3 0.094/0.327 0.937/0.853 8.8/2.0 0.25 2 2.9/2.6 0.55
Semet 132,242/20,619 3.5 0.096/0.354 0.958/0.887 15.7/4.5 0.19 8 2.0/1.7 0.72
Native 2 260,579/44,864 2.7 0.095/0603 0.999/0.100 18.6/2.5 – – – –
Native 3 242,137/49,285 2.6 0.093/0.654 0.977/0.261 14.9/1.9 – – – –
Native 2+3 500,988/49,366 2.6 0.102/0.659 0.978/0.259 22.2/1.9 – – – –
KOS10 and KOS20, 10 mM and 20 mM K2OsO4 overnight soak,
respectively; PIP and PIP05, 1.0 mM and 0.5 mM di-µ-
iodobis(ethylenediamine)diplatinum(II)nitrate overnight soak,
respectively; Semet, selenomethionine-subsituted protein. Native 2 and
native 3 were collected at BW7A at the EMBL outstation in Hamburg.
R factors were calculated according to Diederichs and Karplus [60]
and gave the following results. For native 2, Rmeas = 0.104, pooled
coefficient of variation (PCV [60] ) = 0.163 and Imerge = 0.092. For
native 3, Rmeas = 0.098, PCV = 0.166 and Imerge = 0.098. For native
2+3, Rmeas = 0.105, PCV = 0.174 and Imerge = 0.068. *Rsym = ΣΣ |
I(hkl; i) –<I(hkl>/ΣΣ I(hkl; i), where I(hkl; i ) is the ith measurement of
the reflection hkl; <I(hkl)> is the corresponding mean value. †Riso = Σ |
Ideri(hkl) – Inati(hkl)| / ΣInati(hkl). ‡Phasing power = fH /<E>, where fH is
the heavy-atom amplitude and <E> the mean lack of closure. The
values given for the phasing power were calculated using SHARP;
these figures are much higher than those computed using MLPHARE.
§Rcullis = Σ | FPH ± (FP + Fhcalc) | / Σ (FPH ± – FP), where the summation
is over centric reflections only.
given in Table 2. The mean two-dimensional figures of merit at 3.1 Å
resolution were 0.54 and 0.65 for acentric and centric reflections,
respectively. The electron-density map showed a clear solvent bound-
ary and many secondary structure elements and was improved greatly
using the solvent flipping procedure incorporated into the program
SOLOMON [53]. Here the flip factor was optimised to a value of –0.6
(solvent content 0.75) by monitoring the relative flatness of a solvent
patch excluded from modifications. The improved phase set was used
to compute a map at 3.1 Å resolution which allowed tracing of the
complete chain with the exception of residues 1–10 and 481–483
which are disordered. Model building was performed using the
program O [54] and was greatly aided by the program DEJAVU [55],
which identified the fold in a very early stage of the model building. The
initial model was subjected to slow-cooling torsion angle refinement
[56] and restrained least-squares or restrained maximum-likelihood
refinement using the programs X-PLOR [57] and REFMAC [58]. The
use of individual restrained B factors was justified by an equal drop in
R factor and Rfree of about 5% (2760 test set reflections) [59]. A bulk-
solvent mask and an overall anisotropic B factor (b11 = b22 = –3.7 Å2,
b33 = +30.6 Å2, b12 = 1.1 Å2) were applied. Model rebuilding was
effected using the program O and in the final cycles water molecules
were put in at stereochemically reasonable positions. These water mol-
ecules were only retained during refinement if the B factor remained
below 60 Å2.
Accession numbers
The coordinates of the cSHMT structure have been deposited in the
Brookhaven Protein Data Bank with accession code 1BJ4.
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